Acute Coronary Syndrome Flashcards
Plavix *
clopidogrel
prodrug
class - P2Y12 inhibitor/antagonist
classified as thienopyridine
MOA: active metabolite irreversibly binds to the platelet ADP-P2Y12 receptor, preventing ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation.
Dosing:
LD(Loading Dose): 300-600mg PO (600mg for PCI)
MD(Maintenance Dose): 75mg PO daily
Indication: for Acute Coronary Syndrome (UA/NSTEMI/STEMI) or as secondary prevention in patients with a history of MI, stroke or PAD
Effient *
prasugrel
prodrug
classified as thienopyridine
class - P2Y12 inhibitor/antagonist
MOA: active metabolite irreversibly binds to the platelet ADP-P2Y12 receptor, preventing ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation.
Brillinta *
ticagrelor
class - P2Y12 inhibitor/antagonist
MOA: active metabolite (which is reversible) binds to the platelet ADP-P2Y12 receptor, preventing ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation.
ReoPro **
abciximab
currently unavailable in US
Integrilin **
eptifibatide
Aggrastat
tirofiban
Zontivity
vorapaxar
Activase
alteplase
TNKase
tenecteplase
Boxed Warnings with Plavix
clopidogrel is a prodrug. Effectiveness depends on the conversion to an active metabolite, Mainly by CYP2C19.
Poor metabolizers of CYP2C19 exhibit higher cardiovascular events than patients with normal CYP2C19 function.
Tests to check CYP2C19 genotype can be used as an aid in determining a therapeutic strategy. Consider alternative treatments in patients identified as CYP2C19 poor metabolizers.
Contraindications with Plavix
Active serious bleeding (GI bleed, intracranial hemorrhage)
Warnings with Plavix
Bleeding risk (stop 5 days prior to elective surgery), DO NOT USE with omeprazole and esomeprazole, premature discontinuation ( increase risk of thrombosis), (TTP) thrombotic thrombocytopenic purpura
Boxed Warnings with Effient
Contraindications with Effient
Warnings with Effient
Pearls with Effient
ACS
Acute Coronary syndrome
Acute Coronary Syndrome(ACS) results from _______
plaque build up (atherosclerosis) in the coronary arteries. The plaques are made up of fatty deposits that cause the arteries to narrow, making blood flow more difficult.
The plaque can rupture, leading to clot(thrombus) formation and sudden, reduced blood flow(ischemia) to the heart. This causes an imbalance between myocardial oxygen supply and myocardial oxygen demand.
Risk factors for ACS
men > 45 , women > 55 ( or early hysterectomy), Family Hx: first degree relative with a coronary event before 55 years (men) or 65 years (women), smoking, hypertension, known coronary artery disease, dyslipidemia, diabetes, chronic stable angina, lack of exercise, excessive alcohol,
classic symptoms of an ACS include:
chest pain (often described as discomfort, pressure or squeezing), lasting > or = 10 minutes, severe dyspnea, diaphoresis, syncope/presyncope and/or palpitations
symptoms can occur at rest, or may be precipitated by minimal exertion, exercise, cold weather, extreme emotions, stress or sexual intercourse.
which individuals are less likely to experience the classic symptoms of and ACS?
females, the elderly, and patients with diabetes
__________ is a medical emergency. Patients with sublingual nitroglycerin should use one dose every 5 minutes for up to 3 doses to relieve chest pain. If chest pain is not improved or is worse five minutes after the first dose, they should call 911 immediately.
(ACS) Acute Coronary Syndrome
(ACS) Acute Coronary Syndrome encompasses _________ and _________
(NSTE-ACS) = non-ST segment elevation acute coronary syndromes
&
(STEMI) = ST-segment elevation myocardial infarction
(NSTE-ACS) non-ST segment elevation acute coronary syndromes describes both __________ and _________. These types of ACS are ___________ upon presentation. The types of ACS are differentiated based on ____________
(UA) Unstable Angina
(NSTEMI) non-ST segment elevation myocardial infarction
indistinguishable
ECG findings, the detection of cardiac enzymes and the extent of blockage in the affected artery.
The measurement of biochemical markers (________), released into the blood stream when myocardial cells die, helps establish the diagnosis.
cardiac enzymes
cardiac troponins _______ and _________ are the most sensitive and specific biomarkers for ACS. Levels should be obtained at presentation and 3-6 hours after symptom onset in all patients with ACS symptoms.
I and T (TnI and TnT)
(UA) Unstable angina
symptoms ________
cardiac enzymes _________
ECG changes ___________
blockage ___________
chest pain
negative
none or transient ischemic changes*
partial blockage
- ST segment depression or prominent T-wave inversion
(NSTEMI) non-ST segment elevation myocardial infarction
symptoms ________
cardiac enzymes _________
ECG changes ___________
blockage ___________
chest pain
positive
none or transient ischemic changes*
partial blockade
- ST segment depression or prominent T-wave inversion
(STEMI) ST-segment elevation myocardial infarction
symptoms ________
cardiac enzymes _________
ECG changes ___________
blockage ___________
chest pain
positive
ST segment elevation**
complete blockade
**Meeting defined criteria in > or = 2 continuous leads (leads looking at the same area of the heart
cardiac enzymes ________ and ________ are less sensitive markers but may still be monitored in clinical practice
(CK-MB) Creatine kinase - myocardial isoenzyme
myoglobin